Background. A multicenter study was performed to evaluate the reproducibility of Ceftazidime/Avibactam on a MicroScan Dried Gram Negative MIC (MSDGN) Panel.
Background. The current standard technique for diagnosis of bloodstream infection (BSI) is through the detection of micro-organisms using automated blood culture systems and subsequent phenotypic antimicrobial susceptibilty testing (AST) techniques that require 24-48 hours to generate results. The aim of this study was to evaluate the Accelerate Pheno™ system (AXDX), which utilises fluorescent in situ hybridization and morphokinetic cellular analysis to identify bacteria from positive blood cultures and perform AST in less than 7 hours.
Methods. The Accelerate PhenoTest™ BC kit was used to test 15 gram-negative isolates with a range of AST profiles, from simulated blood cultures. Isolates included 10 target organisms; Escherichia coli (n = 2), Enterobacter sp. (n = 2), Klebsiella sp., Proteus sp., Citrobacter sp., Pseudomonas aeruginosa, Acinetobacter baumannii, Serratia marcescens and 5 non-target organisms. AXDX results were compared with MALDI-ToF MS identification and BD Phoenix™ automated AST results. To evaluate the reproducibility of AXDX analysis, all isolates were tested at two different sites, six in duplicate.
Results. A total of 37 tests were performed. AXDX correctly identified 90% (9/10) of the target organisms, and correctly identified 100% (5/5) of non-target organisms as such. One isolate of Citrobacter sp. was initially misidentified as Enterobacter sp. but was correctly identified twice on repeat testing. The AST results demonstrated 93% (244/262) essential agreement (MIC within <1 dilution) and 90% (237/262) categorical agreement (same S/I/R interpretation) compared with conventional laboratory methods. For AST results, between-site reproducibility (MIC within <1 dilution) was 97%.
Conclusion. The Accelerate PhenoTest™ BC kit can provide rapid identification alongside phenotypic AST results direct from positive blood cultures. In this study, the assay demonstrated high reproducibility and good correlation with conventional laboratory methods. By reducing the time to AST results the Accelerate Pheno™ system has the potential to produce actionable results for the management of BSI and enable earlier escalation or de-escalation of antibiotic therapy. This also has the potential to improve patient outcomes by reducing morbidity and mortality. Background. Delayed reporting of antibiotic susceptibility results impacts the treatment of patients with bacteremia. We evaluated the sensitivity and specificity of DST of GNB from pellets used for rapid identification (ID) directly from +BC.
Methods. Pellets from 1.5 mL of +BC in our lab have been used for the direct speciation of bacteria. For 109 samples identified as aerobic GNB on these pellets, the remainder of the sample was suspended in 0.45% NaCl to a standard density of 0.5 McFarland. Specimens were then processed using Vitek2 TM N216 cards according to the manufacturer's instructions. Results were compared with those from susceptibility testing from plate subculture 18 -24 hours later. Antibiotics not reported on blood isolates from this card including were not included in the analysis. To increase the number of antibiotic-resistant organisms (ARO), 35 highly resistant GNB were seeded into BC and processed as above.
Results. Clinical specimens tested included 80 E. coli (EC), 14 K. pneumoniae, 5 K. oxytoca, 3 E. cloacae, and 2 P. aeruginosa, 2 P. mirabilis, and one each of S. marscesens, S. typhi, P. vulgaris, and R. planticola. DST results were available on average 24.8 (95% CI 23.4 -26.2) hours earlier. Of 235 antibiotic resistant results, there were 2 very major errors (VME) (0.85%) with DST -both in EC against cefepime (CPM). These isolates flagged as possible ESBL-producers based on the ceftazidime (CTAZ) or ceftriaxone (CTRX) DST. Two major errors (MAE) occurred with trimpethoprim-sulfamethoxazole (0.85%). Minor errors occurred in 17 cases all within one dilution of the standard MIC. All of the other tests resulted in categorical or essential agreement.
On the ARO tested, there were 405 antibiotic resistant results on standard testing. In this set, there were 10 VME (0.25%); including 1 amikacin, 2 CPM, 1 CTRX, 6 meropenem (MERO). Mechanisms of resistance in these VME included organisms with VIM (6), OXA (3), and KPC (1) genes. All VME with CPM, MERO, and CTRX were flagged as potential ESBL-producers base on the CTAZ result. One MAE with cefoxitin.
Conclusion. DST from BC produces reliable results 24 hour sooner than standard testing. Isolates flagged for potential resistance to thirdgeneration cephalosporin and/ or carbapenem on DST need further testing.
Disclosures. All authors: No reported disclosures. Saturday, October 7, 2017: 12:30 PM Background. This study evaluated AXDX (uses FISH/real-time microscopy to obtain ID/AST direct from +BC in <7h) for accuracy against reference mass spectrometry (MS, VITEK ® MS, bioMérieux) and broth microdilution (BMD), respectively. AXDX TAT was timed against current reporting for ID using MS and VITEK ® 2 (VT2, bioMérieux) for AST (VT2 data not presented).
Prospective Evaluation of
Methods. Blood from 173 semi-consecutive +BC tested in BacT/Alert ® (bioMérieux) with GNB on Gram were tested in AXDX. Susceptible/intermediate/ resistant (S/I/R) interpretations were as per CLSI-M100-S27 for cefazolin (CFZ), ceftriaxone (CRO), ceftazidime (CAZ), piperacillin/tazobactam (TZP), ertapenem (ETP), meropenem (MEM), ciprofloxacin (CIP), gentamicin (GM), tobramycin (TOB), and amikacin (AN). ID and AST results were combined across GNB-genera for assessment as per Cumitech 31A for ≥90% agreements [identificatoin, essential (EA); categorical (CA)] and errors [very major (VME) <3%; combined major/minor (ME/mE) <7%].
Results. 142 (82.1%) AXDX results were evaluable (ID-agreed/AST-reported) for 78 Escherichia coli, 27 Klebsiella species, 17 Pseudomonas aeruginosa, 5 Enterobacter cloacae, 8 Serratia marcescens, 3 Proteus mirabilis, 2 Acinetobacter baumannii and 2 Citrobacter freundii as seen tabulated below. Limits were exceeded for underlined values but 95% confidence intervals (CI) overlapped acceptable limits except in values marked with asterisks [EA (CAZ: 68.7-82.7), ME/mE (CFZ: 5.1-16.8; CAZ: 10-21.9; TZP: 9.2-20.8)]. VME were not evaluable (NE) for TZP, ETP, MEM, or AN due to insufficient numbers of GNB resistant to these agents.
